Alaa Kassim Ali

Dr. Alaa Ali is an Associate Scientist specializing in cancer immunotherapy. His work focuses on identifying and exploiting cancer vulnerabilities to develop innovative treatment strategies. He engineers next-generation chimeric antigen receptor (CAR) NK and T cells as novel immunotherapies, aiming to improve the precision and effectiveness of immune-based treatments. At KFSHRC, he leads projects targeting a range of tumor-associated antigens using genetically engineered immune cells, with the goal of advancing translational cancer therapies.

Natural Killer Cell Biology.

Cancer immunotherapy.

CAR NK and CAR T cell engineering.

Adoptive Cell Therapy.

Immunocytokine engineering.

Dr. Alaa Ali completed his PhD in Microbiology and Immunology at the University of Ottawa, Canada. He subsequently pursued a postdoctoral fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, USA. His research has focused on Natural Killer cell development and function, cytokine signaling and responses, and the engineering of cell-based cancer immunotherapies.